Overview

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Status:
Completed

Trial end date:
2021-03-10

Target enrollment:

Participant gender:

Summary

E7080-G000-304 is a multicenter, randomized, open-label, noninferiority Phase 3 study to compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment in participants with unresectable Hepatocellular Carcinoma (HCC).

Phase:

Phase 3

Details

Lead Sponsor:

Eisai Limited

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Lenvatinib
Niacinamide
Sorafenib